Member Info for BuenaVista

Great news for Avacta and anyone who follows HurstBot! Long live the IPO!!!!! 75/9 and 1000/ on the bid next week on NY size buying by bagels.🥱

I've written previously that pre|CISION isn't a 'plug-and-play' technology because the capping groups of AVA6000 and AVA3996 are different, so what capping group to use for a third substrate? AVA6000's or AVA3996's or something else? And how to happen across what's the best other than by educated trial and error using some computational chemistry - aka molecular modelling)?

So now it looks as though Avacta look to be well down the track of, if not plug-and-play exactly, then a guide to the supermarket shelves of chemical groupings.

Totally irrelevant to Avacta

Ten warheads have been designed and characterised both in vitro and in vivo (in animals, almost certainly rodents). Also 40 capping groups and 20 self-immolative linkers have been employed. All this has been done to develop Avacta's 'pre|CISION computational design algorithms'.

I didn't read slide 5 at 4:05 and Francis's commentry as meaning that there are 10 candidates in the pipeline, just that 10 warheads had been used with the various capping groups and self-immolative linkers to develop Avacta's understanding (through their molecular modelling) of what structures best fit and are best cleaved by FAP. It may be that they have 10 candidates, or even more, from those 10 warheads but, more importantly, they are starting to get a good idea about how other warheads (other companies' warheads!) could be 'pre|CISIONed' to be optimally cleaved by FAP.

Well there's been news of presenting at EORTC plus the 2 abstracts and there will be the 2 posters themselves and possibly also videos that explain the posters ahead of the presentation on the 30th so as not to 'waste' time then. Difficult to think there will be anything else before the 30th unless there are things that need to be RNS'ed.

When have Avacta, or anyone, ever released information about their pipeline outside a conference and immediately before a presentation to present their pipeline?

What specifically do you think might be released about the other candidates before 30 October? Structures, in virto activities, in vivo activities? I doubt we'll get much, if any, of this at the R&D Spotlight day presentation even - unless any patents disclosing such information have been published.

@Timster, what else could they possibly announce about the pipeline? It'll just be links to the EORTC posters at the end of next week and possibly explanatory videos.

There's no new news. Rise is just people fired up by the rampy chat in Twatter.

Never trust a person making predictions.

Particularly if they come with definite numbers.

Especially if the person is clueless about the subject.

Such crass behaviour really does have real-life consequences.

Re: "Enhertu (Trastuzumab Deruxtecan), Exatecan (Deruxtecan being a derivative), Trodelvy (Sacituzumab Govitecan) – plus several other products delivering SN-38, or even Keytruda (Pembolizumab)?"

Anything ending -zumab is an antibody, so the topoisomerase I inhibitor warheads listed here are just the deruxtecan, exatecan and govitecan (all are lowercase generic, not capitalised Trade names) and govitecan is also known as SN-38 (its research code, like AVA6000, AVA3996, AVA6103, etc).

Computational chemistry was used to design the pipeline. Starting with the 3D crystal structure of FAP and its receptor, as mentioned in the video, a computer modelling program would have been used to model the fitting of various designs of pipeline candidates into the receptor space. SAR was mentioned in the video. That stands for 'structure activity relationship' and is applied as a feedback system in that designed structures that show some activity in vitro and then in vivo are fed back into the computational chemistry modelling in an iterative way (tweaking) to optimise the efficacy.

@B2HS2L Affibody is a registered trademark, just like Affimer is. Apart from the ® appearing after the terms (when written fully and correctly), they are also capitalised words: capitalised = trade/brand name, lowercase = generic name/term.

Well Affibody® molecules are real and are scaffold proteins/antibody mimics being developed by Swedish company Affibody Medical AB, similar concept to Avacta's proprietary Affimer® technology but not the same.

AI got it's wired crossed. Just like it did with this Avacta/Elicio partnership thing.

What is the evidence that Avacta has partnered with Elicio? I mean, beyond what's come out of the Gemini app.

I don't know what this Gemini app is but it seems to have access to a whole other world of information that is separate from what Avacta has put in the public domain. Or there's been a glitch.

Anyway, this is the company that has the Affibody® molecules IP: https://www.affibody.se/research-development/our-technology/

Then take away the number you first thought of.

Never trust a person making predictions.

Particularly if they come with definite numbers.

Especially if the person's clueless about the subject.

Such crass behaviour really does have real-life consequences.

It's not harmless white noise. It can have real life consequences for people who believe the rubbish this HurstBot account spews out.

HurstBot wrote this this morning: "and go short Fidelity China Special situations fund, 20% downside expected ! "

HurstBot is an idiot - a program written by jokers - that's full to overflowing with BS.

https://www.lse.co.uk/profiles/hurst10/

I was putting down a marker to see what the SP actually does.

240 open so looking at 192

HurstBot says short this for 20% downside.